China's Sinopharm COVID-19 Vaccine Shows 79.34% Efficacy

China's Sinopharm Group SHTDY said Wednesday its COVID-19 vaccine candidate BBIBP-CorV — developed in partnership with Beijing Biological Products Institute Co. Ltd — shows 79.34% efficacy, Reuters reports.

What Happened: Beijing Biological Products Institute's vaccine efficacy rate is based on interim results from Phase 3 clinical trials but the firm did not give further details. In October, the Lancet had published data from the company's Phase 1/2 clinical trials.

Reuters notes that Beijing Biological has applied to the National Medical Products Administration for conditional approval of BBIBP-CorV, which would allow limited use of the vaccine among the general public in China.

Leading COVID-19 vaccine candidates that have received conditional approval in the U.S. showed higher efficacy rates; 94.1% for Moderna Inc's MRNA mRNA-1273, 95% for Pfizer Inc PFE/BioNTech SE's BNTX BNT162b2

AstraZeneca plc's AZN AZD1222 COVID-19 vaccine candidate, developed in partnership with Oxford University, showed efficacy between 70% and 90%.

Price Action: SHTDY shares closed at $11.53 on Tuesday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsGlobalMediaGeneralclinical trialsCOVID-19 VaccineReuters
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!